383 related articles for article (PubMed ID: 33046796)
1. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.
He Q; Lin Z; Wang Z; Huang W; Tian D; Liu M; Xia L
Oncogene; 2020 Dec; 39(50):7279-7295. PubMed ID: 33046796
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 1β-mediated HOXC10 Overexpression Promotes Hepatocellular Carcinoma Metastasis by Upregulating PDPK1 and VASP.
Dang Y; Chen J; Feng W; Qiao C; Han W; Nie Y; Wu K; Fan D; Xia L
Theranostics; 2020; 10(8):3833-3848. PubMed ID: 32206125
[No Abstract] [Full Text] [Related]
3. ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY.
Liu D; Zhang T; Chen X; Zhang B; Wang Y; Xie M; Ji X; Sun M; Huang W; Xia L
Cell Death Dis; 2021 Nov; 12(12):1113. PubMed ID: 34839358
[TBL] [Abstract][Full Text] [Related]
4. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation.
He Q; Huang W; Liu D; Zhang T; Wang Y; Ji X; Xie M; Sun M; Tian D; Liu M; Xia L
Theranostics; 2021; 11(12):5759-5777. PubMed ID: 33897880
[No Abstract] [Full Text] [Related]
5. HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET.
Zhang T; Wang Y; Xie M; Ji X; Luo X; Chen X; Zhang B; Liu D; Feng Y; Sun M; Huang W; Xia L
J Exp Clin Cancer Res; 2022 Sep; 41(1):275. PubMed ID: 36109787
[TBL] [Abstract][Full Text] [Related]
6. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling.
Yu J; Xia X; Dong Y; Gong Z; Li G; Chen GG; Lai PBS
Theranostics; 2021; 11(5):2123-2136. PubMed ID: 33500715
[No Abstract] [Full Text] [Related]
7. Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-κB pathway.
Tey SK; Tse EYT; Mao X; Ko FCF; Wong AST; Lo RC; Ng IO; Yam JWP
Cancer Lett; 2017 Dec; 411():150-161. PubMed ID: 28989054
[TBL] [Abstract][Full Text] [Related]
8. PRRX1 deficiency induces mesenchymal-epithelial transition through PITX2/miR-200-dependent SLUG/CTNNB1 regulation in hepatocellular carcinoma.
Chen W; Wu J; Shi W; Zhang G; Chen X; Ji A; Wang Z; Wu J; Jiang C
Cancer Sci; 2021 Jun; 112(6):2158-2172. PubMed ID: 33587761
[TBL] [Abstract][Full Text] [Related]
9. T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1.
Ji X; Chen X; Zhang B; Xie M; Zhang T; Luo X; Liu D; Feng Y; Wang Y; Sun M; Li C; Huang W; Xia L
Oncogene; 2022 Apr; 41(15):2225-2238. PubMed ID: 35217793
[TBL] [Abstract][Full Text] [Related]
10. Sox12, a direct target of FoxQ1, promotes hepatocellular carcinoma metastasis through up-regulating Twist1 and FGFBP1.
Huang W; Chen Z; Shang X; Tian D; Wang D; Wu K; Fan D; Xia L
Hepatology; 2015 Jun; 61(6):1920-33. PubMed ID: 25704764
[TBL] [Abstract][Full Text] [Related]
11. Standard CD44 modulates YAP1 through a positive feedback loop in hepatocellular carcinoma.
Fan Z; Xia H; Xu H; Ma J; Zhou S; Hou W; Tang Q; Gong Q; Nie Y; Bi F
Biomed Pharmacother; 2018 Jul; 103():147-156. PubMed ID: 29649630
[TBL] [Abstract][Full Text] [Related]
12. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma.
Xia L; Huang W; Tian D; Zhu H; Zhang Y; Hu H; Fan D; Nie Y; Wu K
J Hepatol; 2012 Sep; 57(3):600-12. PubMed ID: 22613004
[TBL] [Abstract][Full Text] [Related]
13. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.
Bozkaya G; Korhan P; Cokaklı M; Erdal E; Sağol O; Karademir S; Korch C; Atabey N
Mol Cancer; 2012 Sep; 11():64. PubMed ID: 22962849
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma.
Xia L; Huang W; Tian D; Zhu H; Qi X; Chen Z; Zhang Y; Hu H; Fan D; Nie Y; Wu K
Hepatology; 2013 Feb; 57(2):610-24. PubMed ID: 22911555
[TBL] [Abstract][Full Text] [Related]
15. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
16. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization.
Zhao X; Wang X; You Y; Wen D; Feng Z; Zhou Y; Que K; Gong J; Liu Z
Exp Cell Res; 2020 Jun; 391(1):111979. PubMed ID: 32246992
[TBL] [Abstract][Full Text] [Related]
17. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
[TBL] [Abstract][Full Text] [Related]
18. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met.
Korhan P; Erdal E; Atabey N
Biochem Biophys Res Commun; 2014 Aug; 450(4):1304-12. PubMed ID: 25058462
[TBL] [Abstract][Full Text] [Related]
19. EB2 promotes hepatocellular carcinoma proliferation and metastasis via MAPK/ERK pathway by modulating microtubule dynamics.
Zhong FJ; Li YM; Xu C; Sun B; Wang JL; Yang LY
Clin Sci (Lond); 2021 Apr; 135(7):847-864. PubMed ID: 33755094
[TBL] [Abstract][Full Text] [Related]
20. STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway.
Zhang R; Gao X; Zuo J; Hu B; Yang J; Zhao J; Chen J
Cancer Sci; 2020 Feb; 111(2):406-417. PubMed ID: 31785057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
